Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Xencor, Inc. before investing.

In this article, we go over a few key elements for understanding Xencor, Inc.’s stock price such as:

• Xencor, Inc.’s current stock price and volume
• Why Xencor, Inc.’s stock price changed recently
• Upgrades and downgrades for XNCR from analysts
• XNCR’s stock price momentum as measured by its relative strength

About Xencor, Inc. (XNCR)

Before we jump into Xencor, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn’s disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer’s disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Want to learn more about Xencor, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Xencor, Inc..

Xencor, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Xencor, Inc.’s stock price was $17.320.

Xencor, Inc. is down 0.35% from its previous closing price of $17.380.

During the last market session, Xencor, Inc.’s stock traded between $17.205 and $17.830. Currently, there are approximately 74.41 million shares outstanding for Xencor, Inc..

Xencor, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Xencor, Inc. Stock Price History

Xencor, Inc.’s (XNCR) price is currently up 17.74% so far this month.

During the month of November, Xencor, Inc.’s stock price has reached a high of $17.830 and a low of $13.120.

Over the last year, Xencor, Inc. has hit prices as high as $27.240 and as low as $6.920. Year to date, Xencor, Inc.’s stock is down 24.63%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Xencor, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there was 1 analyst who downgraded Xencor, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Xencor, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Xencor, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Xencor, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Xencor, Inc. (XNCR) by visiting AAII Stock Evaluator.

Relative Price Strength of Xencor, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Xencor, Inc. has a weighted four-quarter relative price strength of 17.80%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Xencor, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Xencor, Inc. Stock Price: Bottom Line

As of November 28, 2025, Xencor, Inc.’s stock price is $17.320, which is down 0.35% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Xencor, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.